Last reviewed · How we verify
VARIVAX™ New Seed Process
VARIVAX is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.
VARIVAX is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection. Used for Prevention of varicella (chickenpox) in children and adults.
At a glance
| Generic name | VARIVAX™ New Seed Process |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened form of the varicella-zoster virus (Oka strain) that replicates in host cells but does not cause disease in immunocompetent individuals. This triggers both cellular and humoral immune responses, generating antibodies and T-cell mediated immunity against the virus. The new seed process refers to an updated manufacturing method for producing the vaccine strain.
Approved indications
- Prevention of varicella (chickenpox) in children and adults
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash (varicella-like)
- Myalgia
Key clinical trials
- Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |